Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) have been given a consensus recommendation of “Moderate Buy” by the fourteen research firms that are covering the stock, Marketbeat Ratings reports. Three analysts have rated the stock with a hold recommendation, ten have issued a buy recommendation and one has given a strong buy […]
Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) had its price objective cut by Citigroup from $70.00 to $67.00 in a research note published on Friday, Benzinga reports. They currently have a buy rating on the stock. Other analysts have also recently issued reports about the company. Bank of America upgraded Apellis Pharmaceuticals from a neutral rating […]
Apellis Pharmaceuticals (NASDAQ:APLS) PT Lowered to $56 00 etfdailynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from etfdailynews.com Daily Mail and Mail on Sunday newspapers.
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) was the recipient of a significant increase in short interest in the month of October. As of October 15th, there was short interest totalling 18,590,000 shares, an increase of 10.9% from the September 30th total of 16,770,000 shares. Based on an average trading volume of 4,170,000 shares, […]
Handelsbanken Fonder AB lifted its stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 14.7% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 17,200 shares of the company’s stock after acquiring an additional 2,200 shares during the period. Handelsbanken Fonder […]